FOLFIRINOX or nab-paclitaxel plus gemcitabine in metastatic pancreatic adenocarcinoma: an observational study
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
FOLFIRINOX or nab-paclitaxel plus gemcitabine in metastatic pancreatic adenocarcinoma: an observational study
Authors
Keywords
-
Journal
Future Oncology
Volume -, Issue -, Pages -
Publisher
Future Medicine Ltd
Online
2022-05-24
DOI
10.2217/fon-2021-1142
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Liposomal irinotecan plus fluorouracil/leucovorin versus FOLFIRINOX as the second-line chemotherapy for patients with metastatic pancreatic cancer: a multicenter retrospective study of the Korean Cancer Study Group (KCSG)
- (2021) H.S. Park et al. ESMO Open
- Overall survival in patients with pancreatic cancer receiving matched therapies following molecular profiling: a retrospective analysis of the Know Your Tumor registry trial
- (2020) Michael J Pishvaian et al. LANCET ONCOLOGY
- Modified FOLFIRINOX as a second-line therapy following gemcitabine plus nab-paclitaxel therapy in metastatic pancreatic cancer
- (2020) Masashi Sawada et al. BMC CANCER
- Choice of first line systemic treatment in pancreatic cancer among national experts
- (2020) M. Glatzer et al. PANCREATOLOGY
- Pancreatic cancer
- (2020) Jonathan D Mizrahi et al. LANCET
- FOLFIRINOX as second-line chemotherapy for advanced pancreatic cancer: A subset analysis of data from a nationwide multicenter observational study in Japan
- (2020) Noritoshi Kobayashi et al. PANCREATOLOGY
- The actual 5-year survivors of pancreatic ductal adenocarcinoma based on real-world data
- (2020) Axel Bengtsson et al. Scientific Reports
- Second-Line Gemcitabine Plus Nab-Paclitaxel for Patients with Unresectable Advanced Pancreatic Cancer after First-Line FOLFIRINOX Failure
- (2019) Naoki Mita et al. Journal of Clinical Medicine
- Comparative Effectiveness of Gemcitabine plus Nab-Paclitaxel and FOLFIRINOX in the First-Line Setting of Metastatic Pancreatic Cancer: A Systematic Review and Meta-Analysis
- (2019) Sara Pusceddu et al. Cancers
- Clinical Safety and Efficacy of Secondary Prophylactic Pegylated G-CSF in Advanced Pancreatic Cancer Patients Treated with mFOLFIRINOX: A Single-center Retrospective Study
- (2019) Kentaro Yamao et al. INTERNAL MEDICINE
- Neoadjuvant Treatment in Locally Advanced Pancreatic Cancer (LAPC) Patients with FOLFIRINOX or Gemcitabine NabPaclitaxel: A Single-Center Experience and a Literature Review
- (2019) Fabiana Napolitano et al. Cancers
- Real‐world outcomes of FOLFIRINOX vs gemcitabine and nab‐paclitaxel in advanced pancreatic cancer: A population‐based propensity score‐weighted analysis
- (2019) Kelvin K. W. Chan et al. Cancer Medicine
- Organoid profiling identifies common responders to chemotherapy in pancreatic cancer
- (2018) Hervé Tiriac et al. Cancer Discovery
- Diagnosis and management of pancreatic cancer in adults: A summary of guidelines from the UK National Institute for Health and Care Excellence
- (2018) Derek O'Reilly et al. PANCREATOLOGY
- Pancreatic cancer: A review of clinical diagnosis, epidemiology, treatment and outcomes
- (2018) Andrew McGuigan et al. WORLD JOURNAL OF GASTROENTEROLOGY
- Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
- (2013) Daniel D. Von Hoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
- (2011) Thierry Conroy et al. NEW ENGLAND JOURNAL OF MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now